Shares of Mesoblast Ltd. (NASDAQ:MESO) have earned an average recommendation of “Buy” from the six research firms that are presently covering the stock. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $8.63.
Several analysts have recently weighed in on the company. Credit Suisse Group AG lowered Mesoblast from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $10.00 to $5.00 in a report on Tuesday, June 14th. Zacks Investment Research raised Mesoblast from a “sell” rating to a “hold” rating in a report on Tuesday, August 23rd. Finally, Maxim Group reissued a “buy” rating and set a $14.00 price objective on shares of Mesoblast in a report on Wednesday, July 6th.
Mesoblast (NASDAQ:MESO) opened at 4.44 on Wednesday. The firm’s market cap is $335.55 million. The firm’s 50-day moving average price is $4.74 and its 200-day moving average price is $6.03. Mesoblast has a 12 month low of $3.50 and a 12 month high of $13.00.
Hedge funds have recently made changes to their positions in the stock. Prudential PLC raised its stake in shares of Mesoblast by 2.0% in the first quarter. Prudential PLC now owns 1,538,629 shares of the company’s stock valued at $14,802,000 after buying an additional 29,597 shares in the last quarter. Citigroup Inc. raised its stake in shares of Mesoblast by 659,900.0% in the second quarter. Citigroup Inc. now owns 33,000 shares of the company’s stock valued at $131,000 after buying an additional 32,995 shares in the last quarter. OLD Mission Capital LLC bought a new stake in shares of Mesoblast during the first quarter valued at approximately $431,000. Finally, Princeton Capital Management Inc. raised its stake in shares of Mesoblast by 135.4% in the second quarter. Princeton Capital Management Inc. now owns 109,382 shares of the company’s stock valued at $433,000 after buying an additional 62,915 shares in the last quarter. 3.41% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
Receive News & Ratings for Mesoblast Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.